ArticleCancer control : journal of the Moffitt Cancer Center
Trends, Global Comparisons, and Projections of the Burden of Malignant Neoplasm of Bone and Articular Cartilage in China Based on GBD 2021.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundThis study meticulously outlines the evolution of the burden of malignant neoplasm of bone and articular cartilage (MNBAC) among different age and sex groups in China from 1990 to 2021, analyzes the global impact of the disease, and predicts the trend of disease burden up to 2035.MethodsLeveraging public data from the Global Burden of Disease (GBD) database spanning 1990 to 2021, this study thoroughly analyzed the characteristics of the burden of MNBAC in China and globally, including its incidence, prevalence, mortality, and disability-adjusted life years (DALYs). The joinpoint analysis method was employed to calculate the average annual percentage change (AAPC) and its 95% uncertainty interval, revealing the trend of MNBAC's impact. Furthermore, Bayesian age-period-cohort (BAPC) model was used to forecast changes in disease burden leading up to 2035.ResultsBetween 1990 and 2021, the age-standardized incidence rate (ASIR) of MNBAC in China increased from 0.65 to 1.42 per 100 000 people, and the global ASIR rose from 0.97 to 1.11 per 100 000. The AAPC for China's ASIR, age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) were 2.59%, 2.71%, 1.52%, and 1.26%, and the AAPC of ASIR and ASPR of the global burden of MNBAC were 0.44% and 0.51%, respectively. The effect of age and sex on the burden of MNBAC showed significant differences. Forecasting analyses suggest that from 2022 to 2035, the burden of MNBAC in China and globally will show a declining trend.ConclusionsFrom 1990 to 2021, the disease burden of MNBAC in China has been rising among the population, particularly pronounced among older men. Although forecasts indicate a gradual reduction in the future burden of MNBAC, given China's large population base and the increasing trend of population aging, MNBAC will pose a public health challenge in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.